Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization

Alex L. Roederer, Yi Cao, Chia Jung Li, Eunice Lim, David H. Canaday, Stefan Gravenstein, View ORCID ProfileAlejandro B. Balazs
doi: https://doi.org/10.1101/2025.03.01.25323010
Alex L. Roederer
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Cao
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chia Jung Li
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eunice Lim
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Canaday
2Case Western Reserve University School of Medicine, Cleveland, OH
3Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Gravenstein
4Center of Innovation in Long-Term Services and Supports, Veterans Administration Medical Center, Providence, Rhode Island
5Division of Geriatrics and Palliative Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
6Brown University School of Public Health Center for Gerontology and Healthcare Research, Providence, Rhode Island
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandro B. Balazs
1Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, 02139, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alejandro B. Balazs
  • For correspondence: abalazs{at}mgh.harvard.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

SUMMARY

Studies have demonstrated that repeated mRNA vaccination enhances the breadth of neutralization against diverse SARS-CoV-2 variants. However, the development of antibodies capable of neutralizing across the Coronavirinae subfamily is poorly understood. In this study, we analyze serum samples to determine their neutralization breadth and potency and identify their antigenic targets. Using a cohort of older individuals and healthcare workers, we track correlates of broad neutralizing responses, including fusion peptide (FP) antibody elicitation. We find that although broadly neutralizing responses are often a result of RBD-specific antibodies, a rare subset of donors produce FP-specific broadly neutralizing responses. Interestingly, FP-specific antibodies are not observed in COVID-naive individuals irrespective of vaccination regimen, but rather, they occur following natural infection or vaccine breakthrough. This study highlights the epitope targets underpinning broadly neutralizing antibody responses to coronaviruses and suggests that existing vaccines are insufficient to promote the elicitation of FP-directed broadly neutralizing coronavirus antibodies.

Competing Interest Statement

A.B.B. is a founder of Cure Systems LLC. S. G. and D. H. C. are recipients of investigator-initiated grants to their universities from Pfizer to study pneumococcal vaccines, Sanofi Pasteur and Seqirus to study influenza vaccines, Moderna to study respiratory infection, and GSK to study herpes zoster. S. G. is the recipient of an investigator-initiated grant to the university from Genentech on influenza antivirals; reports consulting for GSK, Janssen/Johnson&Johnson, Merck, Novavax, Moderna, Seqirus, Sanofi, and Vaxart; he has received honoraria for speaking for AstraZeneca, Pfizer, Seqirus, Sanofi; reports personal fees from Pfizer; and reports data and safety monitoring board fees from Longevoron and SciClone.

Funding Statement

A.B.B. was supported by NIAID R01s AI174875, AI174276, AI129709-03S1 the NIDA Avenir New Innovator Award DP2DA040254, the NIDA Avant-Garde Award 1DP1DA060607, a Massachusetts Consortium on Pathogenesis Readiness (MassCPR) grant, CDC subcontract 200-2016-91773-T.O.2 and a grant from Coalition for Epidemic Preparedness Innovations (CEPI).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of human samples was approved by Partners Institutional Review Board (protocol 2020P002274).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted March 05, 2025.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization
Alex L. Roederer, Yi Cao, Chia Jung Li, Eunice Lim, David H. Canaday, Stefan Gravenstein, Alejandro B. Balazs
medRxiv 2025.03.01.25323010; doi: https://doi.org/10.1101/2025.03.01.25323010
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Fusion Peptide-Directed Antibodies Elicited by Natural Infection Mediate Broad Sarbecovirus Neutralization
Alex L. Roederer, Yi Cao, Chia Jung Li, Eunice Lim, David H. Canaday, Stefan Gravenstein, Alejandro B. Balazs
medRxiv 2025.03.01.25323010; doi: https://doi.org/10.1101/2025.03.01.25323010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (433)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3307)
  • Dentistry and Oral Medicine (365)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1174)
  • Epidemiology (13391)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5167)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3281)
  • Health Policy (1144)
  • Health Systems and Quality Improvement (1196)
  • Hematology (432)
  • HIV/AIDS (1021)
  • Infectious Diseases (except HIV/AIDS) (14647)
  • Intensive Care and Critical Care Medicine (914)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4941)
  • Nursing (262)
  • Nutrition (733)
  • Obstetrics and Gynecology (887)
  • Occupational and Environmental Health (796)
  • Oncology (2526)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (546)
  • Pediatrics (1303)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4221)
  • Public and Global Health (7522)
  • Radiology and Imaging (1710)
  • Rehabilitation Medicine and Physical Therapy (1016)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (499)
  • Sports Medicine (425)
  • Surgery (550)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (206)